# Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).

> **NCT01624636** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** Placebo
- **DRUG:** LFG316
- **DRUG:** LFG316

## Key facts

- **NCT ID:** NCT01624636
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-12
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01624636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01624636, "Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01624636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*